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Abstract 
Background: Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating 
joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recom-
binant factor VIII (FVIII) product], real world evidence in children is lacking. This report describes a descriptive and 
multivariate analysis of the effectiveness of Kovaltry in children with hemophilia A in the real-world setting, using data 
from medical chart abstraction and cross-sectional surveys of physicians, patients, and caregivers.
Results: Male patients aged < 18 years with moderate or severe hemophilia A, residing in five European countries 
and treated with FVIII were studied. The co-primary endpoints were the annualized bleeding rate (ABR) and the 
annual FVIII utilization rate. Twenty nine patients treated with Kovaltry were included, of whom 93% had severe dis-
ease and 75% were on continuous prophylactic treatment. The mean ABR was 2.66 ± 2.06, with rates decreasing with 
age. The children received on average 2.45 infusions per week, consistent across age groups (median 3; range 1–3). 
There were no reports of inhibitor development or adverse events in the study (AEs), and all patients were satisfied 
or very satisfied with the treatment. An exploratory multivariate analysis suggests no significant difference in ABR or 
units utilized between Kovaltry and some extended half life products in children with severe hemophilia A, though 
characteristics of these patient cohorts were markedly different.
Conclusion: This analysis demonstrates the effectiveness and safety of Kovaltry in a pan-European pediatric popula-
tion with severe hemophilia A.
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Introduction
Hemophilia A is a rare X-linked genetic disorder char-
acterized by deficiency of coagulation factor VIII (FVIII) 
[1–4]. Individuals with severe hemophilia have FVIII 
levels less than 1% of that expected in a healthy person 
[5, 6]. Such patients, if not optimally treated, encounter 
recurrent bleeding episodes causing cumulative damage 
and commonly arthropathy [7, 8].
In Western European countries, around 90% of chil-
dren with severe hemophilia A now have access to spe-
cialist care teams and prophylactic treatment with 
replacement FVIII, which is proven to reduce bleed-
ing events and resultant joint damage [9–12]. Two main 
types of replacement FVIII are now available; standard 
half-life products (SHL) with half-life of around 8–12  h 
[13], and more recently, so-called extended half life prod-
ucts (EHL) [14, 15]. Two EHL products were approved 
in Europe at the time of this study: Elocta (Sobi) in 2015 
[14] and Adynovate (Takeda) in 2018 [15] only for people 
over the age of 12  years. There is little evidence on the 
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relative clinical effectiveness of SHL and EHL products in 
the real world setting and particularly in children.
Kovaltry is an unmodified full-length recombinant SHL 
FVIII product, yet pharmacokinetic analyses have shown 
an increased half-life for Kovaltry when compared with 
traditional FVIII products in adult hemophilia A patients, 
and consistency in terminal half-life for children across 
all age groups [16–19]. Currently there is an evidence gap 
in translation of the improved PK profile to clinical ben-
efits in children: real-world utilization, safety, and effec-
tiveness, particularly in comparison with EHL products.
The primary objective of this study was to describe the 
effectiveness of Kovaltry in children with hemophilia A 
in the real-world setting.
Methods
A nested cohort analysis was conducted utilizing data as 
captured in the Cost of Haemophilia in Europe: a Socio-
economic Survey (CHESS) Pediatrics study [20, 23]. Clin-
ical- and patient-reported data were obtained between 
December 2017 and April 2018 via medical chart 
abstraction, including 12  months of retrospective clini-
cal data and cross-sectional surveys from physicians and 
patients/caregivers. Males aged less than 18  years who 
had moderate or severe hemophilia A; resided in France, 
Germany, Italy, Spain, or the United Kingdom (UK); and 
who were treated with FVIII were included in analyses. 
The co-primary endpoints were the annualized bleeding 
rate (ABR) as reported by the physicians in the survey 
and the annual Kovaltry utilization. Standard descriptive 
analyses were used to describe baseline characteristics 
and outcomes associated with the included patients [21].
In an exploratory analysis, we compared the character-
istics of patients treated with Kovaltry and EHL products 
in this real world setting. The impact of covariates on 
outcome variables was assessed using a generalized lin-
ear model (GLM) procedure with stepwise model selec-
tion to control covariates and minimize the confounding 
effect. ABR was described and included as a covariate in 
the multivariate analysis of treatment utilization. Con-
versely, treatment utilization was included in the ABR 
model. Sensitivity analysis excluded patients having a 
treatment dose considered by the steering committee to 
be unfeasible: < 2.5  IU/kg/week and > 200  IU/kg/week. 
Statistical analyses were performed using SAS® software 
Version 9.4.
The sample size was driven by the full number of eli-
gible patients available in the dataset, with no further 
restrictions. The rarity of haemophilia A often limits the 
sample size available for research, particularly in chil-
dren, and although CHESS Pediatrics provides one of the 
largest datasets in this population, the statistical power is 
limited. As such, all analyses are considered descriptive 
and exploratory.
Results
In the primary descriptive analysis of Kovatry, 29 chil-
dren were included (Table  1). Nearly all patients had 
severe hemophilia (93.1% n = 27). Most were on con-
tinuous prophylaxis at the initiation of the study (74.9%; 
n = 22). Target joints at the study initiation were rare 
(11%).
The mean annual bleeding rate in patients treated 
with Kovaltry was 2.66 (SD ± 2.06). The data demon-
strated a reduction in rates of bleeding according to age 
categories, from 4 ± 2.92 in the youngest children aged 
0–5  years, 2.67 ± 1.84 in those aged 6–11  years, and in 
the sub group aged 12–17 years 1.89 ± 1.69. Around 20% 
of the patients who were receiving Kovaltry were free of 
bleeds; (n = 6). Within the 22 patients receiving Koval-
try prophylactically, the mean ABR was 2.18, and after 
excluding one patient with an unfeasible dosage was 1.90. 
On average, these patients were prescribed 2.45 infusions 
per week (median 3; range 1–3).
There were no reports of inhibitor development or any 
adverse events (AEs) with Kovaltry. Most patients (86.2%; 
n = 25) were considered by their physician to be adher-
ent to their prescribed treatment regimen (missing < 15% 
of infusions). All patients who responded to the linked 
patient survey were satisfied with the treatment, and 60% 
were very satisfied.
Exploratory analysis
In the exploratory analysis, 82 patients were included (22 
Kovaltry and 60 EHL). Characteristics of patients pre-
scribed Kovaltry and EHL differed considerably. Patients 
in the Kovaltry cohort were younger in age, had more 
severe disease, and started prophylactic treatment at a 
younger age. Patients in the EHL cohort were more likely 
to have had recurrent inhibitors, target joints, and dam-
aged joints. The physician-reported adherence rate was 
similar between both groups (Table 1).
The mean ABR in the Kovaltry cohort was lower than 
with EHL (ABR 1.90 ± 1.58 vs 4.14 ± 7.88 respectively, 
P = 0.04). After statistical adjustment for differences in 
baseline patient characteristics (age, severity, utilization, 
presence of target or chronic joints), the difference was 
not statistically significant (ABR 2.18 ± 1.55 vs 4.06 ± 0.90 
respectively (P = 0.31). ABR remained lower in Kovaltry 
treated patients across all age groups (0–11 years 2.36 vs. 
4.33 and 12–17 years 1.63 vs. 3.93 for Kovaltry and EHL, 
respectively) (Fig. 1), and a higher proportion of patients 
in the Kovaltry cohort had zero annual bleed rates when 
compared with EHL (27.3% vs. 10%).
Page 3 of 5O’Hara et al. Orphanet J Rare Dis           (2021) 16:33  
The mean weekly infusion frequency was comparable 
between the Kovaltry and the EHL group (2.43 vs. 2.28) 
and was similar across all age groups.
The calculated median factor utilization was lower in the 
Kovaltry group than in the EHL group (weekly 80.1  IU/
kg vs 89.9 IU/kg; P = 0.43). When adjusting for differences 
in baseline characteristics in multivariate analyses, there 
was a numerical, but not statistically significant, differ-
ence between Kovaltry and EHL cohorts, (74.84 IU/kg vs. 
88.83 IU/kg; P = 0.23).
Table 1 Demographic characteristics of patients receiving Kovaltry and EHL
Patient characteristics All Kovaltry (n = 29) Prophylactic Kovaltry 
(n = 22)
Prophylactic 
EHL (n = 60)
Age group n (%)
 0–5 years 5 (17.2) 3 (13.6) 3 (5.0)
 6–11 years 15 (51.7) 11 (50.0) 15 (25.0)
 12–17 years 9 (31.0) 8 (36.4) 42 (70.0)
Body mass index groups
 Underweight < 18.5 10 (34.5) 8 (36.4) 9 (15.0)
 Normal 18.5–24.9 9 (31.0) 8 (36.4) 40 (66.7)
 Overweight 25–29.9 5 (17.2) 2 (9.1) 6 (10.0)
 Obese 30+ 4 (13.8) 3 (13.6) 4 (6.7)
 Missing 1 (3.4) 1 (4.5) 1 (1.7)
Severity
 Moderate (1–5 IU/dL) 2 (6.9) 2 (9.1) 12 (20.0)
 Severe (< 1 IU/dL) 27 (93.1) 20 (90.9) 48 (80.0)
History of inhibitors
 0 Never 23 (79.3) 17 (77.3) 46 (76.7)
 1 Once 6 (20.7) 5 (22.7) 10 (16.7)
 More than once—recurrence/relapse 0 (0) 0 (0) 4 (6.70)
Treatment regimen at initiation
 Continuous prophylaxis 22 (75.9) 17 (77.3) 24 (40.0)
 Episodic—on demand—treatment 6 (20.7) 3 (13.6) 32 (53.3)
 Intermittent—periodic—prophylaxis 1 (3.4) 2 (9.1) 4 (6.7)
Target joints
 No 26 (89.7) 20 (90.9) 49 (81.7)
 Yes 3 (10.3) 2 (9.1) 11 (18.3)
Chronically damaged joints
 No 26 (89.1) 21 (95.5) 47 (78.3)
 Yes 3 (10.3) 1 (4.5) 13 (21.7)
Treatment adherence
 Fully adherent: missing < 15% of infusions 25 (86.2) 18 (81.8) 51 (85.0)
 Sub-optimally adherent: missing 15–25% of infusions 3 (10.3) 3 (13.6) 7 (11.7)
 Non-adherent: missing > 25% of infusions 0 0 0 (0)
 Not applicable 1 (3.4) 1 (4.5) 2 (3.30)




Annual bleed rates stratified by age groups
EHL Kovaltry
Fig. 1 Annual bleed rates stratified by age group
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Discussion
While randomized clinical trials (RCTs) are recognized 
as the gold standard for evaluating the efficacy of new 
products, in a real-world setting both the characteristics 
of patients and the way in which products are used can 
differ from the trial setting [22, 23]. Therefore, this RWE 
in pediatric patients across Europe adds to the scientific 
knowledge of hemophilia A treatment.
This current analysis supports the strong profile of 
Kovaltry, with a low mean annual bleeding rate of 2.18, 
ranging from 2.67 to 1.89 from the youngest to the oldest 
patients, in line with clinical and pharmacokinetic expec-
tations [17–20]. 100% patient satisfaction and an aver-
age of 2.45 infusions per week were reported. No adverse 
events or inhibitor development was reported, in line 
with previous research [12–14].
The exploratory analysis demonstrates that, at the 
time of the analysis, children prescribed EHL products 
had markedly different characteristics from those pre-
scribed Kovaltry, being typically older and more likely 
to have had recurrent inhibitors, target joints, and dam-
aged joints. The noted non-significant differences in ABR 
and utilization must be interpreted cautiously in light 
of the low sample size, due to the disease rarity, limited 
available EHLs at the time of the study, restriction of use 
to only patients aged above 12  years for Adynovi, and 
potential for residual confounding factors. Full clinical 
details of joint involvement, such as imaging, were also 
not available in the study dataset.
This study highlights the importance of observational 
data to better understand the utilization of new FVIII 
products in the real world, particularly how this may 
impact patient management and outcomes. It also indi-
cates that further research may be warranted to under-
stand the relative value of FVIII products in children.
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